Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Reilly

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
American Heart Journal|June 15, 2016
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tankJames A Reiffel, Jeffrey I Weitz, Paul Reilly, et al.
Integrative Medicine (Encinitas, Calif.)|April 3, 2019
Assuring Quality of Dietary Supplements for Cancer Patients: An Integrative Formulary Systems ApproachCarolyn A Lammersfeld, Michael D Levin, Paul Reilly, et al.
Clinical Toxicology (Philadelphia, Pa.)|May 26, 2016
Idarucizumab for dabigatran overdoseMarijke Peetermans, Charles Pollack, Paul Reilly, et al.
Journal of the American College of Cardiology|June 18, 2013
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillationJohn W Eikelboom, Stuart J Connolly, Robert G Hart, et al.
Journal of the American College of Cardiology|February 25, 2012
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) studyGreg Flaker, Michael Ezekowitz, Salim Yusuf, et al.
Thrombosis and Haemostasis|March 20, 2015
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranStephan Glund, Viktoria Moschetti, Stephen Norris, et al.
The American Journal of Cardiology|August 19, 2015
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)Rangadham Nagarakanti, Lars Wallentin, Herbert Noack, et al.
Journal of the American College of Cardiology|October 5, 2019
Dabigatran Reversal With Idarucizumab in Patients With Renal ImpairmentJohn W Eikelboom, Joanne van Ryn, Paul Reilly, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|March 9, 2019
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trialAiman Alak, Stefan H Hohnloser, Mandy Fräßdorf, et al.
Circulation|January 5, 2012
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trialStefan H Hohnloser, Jonas Oldgren, Sean Yang, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
American Heart Journal|June 15, 2016
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tankJames A Reiffel, Jeffrey I Weitz, Paul Reilly, et al.
Integrative Medicine (Encinitas, Calif.)|April 3, 2019
Assuring Quality of Dietary Supplements for Cancer Patients: An Integrative Formulary Systems ApproachCarolyn A Lammersfeld, Michael D Levin, Paul Reilly, et al.
Clinical Toxicology (Philadelphia, Pa.)|May 26, 2016
Idarucizumab for dabigatran overdoseMarijke Peetermans, Charles Pollack, Paul Reilly, et al.
Journal of the American College of Cardiology|June 18, 2013
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillationJohn W Eikelboom, Stuart J Connolly, Robert G Hart, et al.
Journal of the American College of Cardiology|February 25, 2012
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) studyGreg Flaker, Michael Ezekowitz, Salim Yusuf, et al.
Thrombosis and Haemostasis|March 20, 2015
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranStephan Glund, Viktoria Moschetti, Stephen Norris, et al.
The American Journal of Cardiology|August 19, 2015
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)Rangadham Nagarakanti, Lars Wallentin, Herbert Noack, et al.
Journal of the American College of Cardiology|October 5, 2019
Dabigatran Reversal With Idarucizumab in Patients With Renal ImpairmentJohn W Eikelboom, Joanne van Ryn, Paul Reilly, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|March 9, 2019
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trialAiman Alak, Stefan H Hohnloser, Mandy Fräßdorf, et al.
Circulation|January 5, 2012
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trialStefan H Hohnloser, Jonas Oldgren, Sean Yang, et al.
Pageof 5